Nova Pharma Solutions Berhad Registration No. 197701003731 (34608–K)

Summary of Key Financial Information for the half year ended 30 June 2022

		UNAUDITED INDIVIDUAL 6 months ended 30 June		UNAUDITED CUMULATIVE 6 months ended 30 June	
		<u>2021</u> <u>RM'000</u>	<u>2020</u> RM'000	<u>2021</u> RM'000	<u>2020</u> <u>RM'000</u>
1	Revenue	3,671	2,827	3,671	2,827
2	Profit / (Loss) before tax	1,210	94	1,210	94
3	Profit / (Loss) for the period	910	94	910	94
4	Profit / (Loss) and total comprehensive income / (loss) attributable to owners of the Company	910	94	910	94
5	Basic earnings / (loss) per share (Subunit-sen)	0.61	0.06	0.61	0.06
6	Proposed/Declared dividend per share (Subunit-sen)	-	-	-	-
		Unaudited as at 30 June 2022		Audited as at 31 December 2021	

 Net assets per share (attributable to ordina holders of the comp 	iry equity	0.076		0.069
---	------------	-------	--	-------

Note 1: Basic earnings per share for the current period is computed based on (loss)/profit for the period divided by weighted average number of shares which are detailed in Note C5 of this interim financial report.

		UNAUDITED INDIVIDUAL 6 months ended 30 June		UNAUDITED CUMULATIVE 6 months ended 30 June	
		<u>2022</u> <u>RM'000</u>	<u>2021</u> RM'000	 <u>2022</u> <u>RM'000</u>	<u>2021</u> RM'000
1	Gross interest income	-	-	-	-
2	Gross interest expense	7	5	7	5